Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Chewy Inc (CHWY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Chewy Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Chewy Inc trades at $20.72 (market cap $8.49B). The key difference: Chewy Inc is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Chewy Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | CHWY | |
|---|---|---|
Market Cap | $4.49B | $8.49B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $42.33 |
52-Week Low | $20.06 | $17.51 |
Enterprise Value | $3.69B | $8.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Chewy (CHWY) trades at $20.73, down 0.58% on the day, with a bullish technical signal from moving averages and strong analyst support. The company reported $11.86B in revenue for 2025 with a net income margin of 1.99%, showing improved profitability from prior years. Recent news highlights market share gains through its Autoship program and expansion into pet healthcare services, though the stock faces pressure from lowered 2026 growth expectations.
The outlook remains positive with an 81.58% buy rating from analysts and a $34.92 consensus price target, suggesting significant upside. Key risks include competitive pressures in the pet care sector and execution challenges in integrating new veterinary services. Investors should weigh strong customer loyalty and recurring revenue streams against near-term volatility and margin pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Chewy Inc
Chewy is the largest e-commerce pet care retailer in the U.S., generating $8.9 billion in 2021 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a standalone company in 2019, after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods, like crates, leashes, and bowls.
Read more on CHWY →
